Modality
ASO
MOA
FXIai
Target
AuroraA
Pathway
RNA Splicing
Endometrial CaAML
Development Pipeline
Preclinical
~Sep 2009
→ ~Dec 2010
Phase 1
~Mar 2011
→ ~Jun 2012
Phase 2
~Sep 2012
→ ~Dec 2013
Phase 3
~Mar 2014
→ ~Jun 2015
NDA/BLA
~Sep 2015
→ ~Dec 2016
Approved
Mar 2017
→ Sep 2028
ApprovedCurrent
NCT07911482
2,181 pts·AML
2019-05→2027-02·Completed
NCT07246948
2,916 pts·Endometrial Ca
2023-10→2026-04·Completed
NCT06386388
176 pts·AML
2017-03→2028-09·Active
5,273 total pts2 indications
CompletedCurrentUpcoming
Catalysts (3)
2026-04-223w awayPh3 Readout· Endometrial Ca
2027-02-0710mo awayPh3 Readout· AML
2028-09-182.5y awayPh3 Readout· AML
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Approved
Active
Approved
Complet…
Approved
Complet…
Catalysts
Ph3 Readout
2026-04-22 · 3w away
Endometrial Ca
Ph3 Readout
2027-02-07 · 10mo away
AML
Ph3 Readout
2028-09-18 · 2.5y away
AML
ActiveCompleted|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07911482 | Approved | AML | Completed | 2181 | DAS28 |
| NCT07246948 | Approved | Endometrial Ca | Completed | 2916 | SeizFreq |
| NCT06386388 | Approved | AML | Active | 176 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| ARG-6988 | Argenx | Preclinical | AuroraA |